Simultaneously they discovered the suppressive cytokine interleukin 10 inhibits antigen-presenting cells, thus regulating development of T H 1 cells. You have full access to this article via your ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is ...

Revelation Biosciences (REVB) announced Gemini priming attenuates the inflammatory response in human peripheral blood mononuclear cells exposed ...

Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...

Mast cells, which are abundant in the airways of asthmatic individuals, act as first responders to viral infections by ...

REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of ...

This review highlights the growing interest in ginsenosides, especially Compound K (CK), as potential anti-aging agents due ...

Several medications now calm painful inflammation in the intestines. Diets free of ultraprocessed foods also help ...

Cancer metastasis, the spread of cancer to organs, is a major cause of cancer-related deaths. Once cancer spreads to multiple ...

A 5-year study of bimekizumab in ankylosing spondylitis encountered no new safety signals, with efficacy sustained even in a conservative analysis with non-responder imputation, according to data ...

Skin aging, an inevitable aspect of the aging process, has gained notable attention in research, particularly in the context of finding effective ...